Patents by Inventor Martin Lenter
Martin Lenter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9211330Abstract: The invention relates to biparatopic A-beta binding polypeptides and, more specifically, to biparatopic A-beta binding polypeptides comprising at least two immunoglobulin single variable domains binding to different epitopes of A-beta. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as Alzheimer's Disease.Type: GrantFiled: August 29, 2013Date of Patent: December 15, 2015Assignee: Ablynx N.V.Inventors: John E. Park, Cornelia Dorner-Ciossek, Stefan Hoerer, Lothar Kussmaul, Martin Lenter, Katharina Zimmerman, Gerald Beste, Toon Laeremans, Pascal Gerard Merchiers, Jo Vercammen
-
Publication number: 20140030275Abstract: The invention relates to biparatopic A-beta binding polypeptides and, more specifically, to biparatopic A-beta binding polypeptides comprising at least two immunoglobulin single variable domains binding to different epitopes of A-beta. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as Alzheimer's Disease.Type: ApplicationFiled: August 29, 2013Publication date: January 30, 2014Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: John E. PARK, Cornelia DORNER-CIOSSEK, Stefan HOERER, Lothar KUSSMAUL, Martin LENTER, Katharina ZIMMERMANN, Gerald BESTE, Toon LAEREMANS, Pascal MERCHIERS, Jo VERCAMMEN
-
Patent number: 8618132Abstract: The present invention relates to alkyne compounds of general formula I wherein the groups and residues A, B, W, X, Y, Z, R1 and R2 have the meanings given in claim 1. The invention further relates to pharmaceutical compositions containing at least one alkyne according to the invention. In view of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.Type: GrantFiled: May 15, 2008Date of Patent: December 31, 2013Assignee: Boehringer Ingelheim Pharma GmbH & Co. KGInventors: Dirk Stenkamp, Stephan Georg Mueller, Gerald Juergen Roth, Thorsten Lehmann-Lintz, Klaus Rudolf, Philipp Lustenberger, Kristen Arndt, Ralf R. H. Lotz, Martin Lenter
-
Patent number: 8614308Abstract: The invention relates to biparatopic A-beta binding polypeptides and, more specifically, to biparatopic A-beta binding polypeptides comprising at least two immunoglobulin single variable domains binding to different epitopes of A-beta. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as Alzheimer's Disease.Type: GrantFiled: September 14, 2012Date of Patent: December 24, 2013Assignee: Boehringer Ingelheim International GmbHInventors: John E. Park, Cornelia Dorner-Ciossek, Stefan Hoerer, Lothar Kussmaul, Martin Lenter, Katharina Zimmermann, Gerald Beste, Toon Laeremans, Pascal Merchiers, Jo Vercammen
-
Publication number: 20130295666Abstract: The present invention pertains to crystals of glucokinase regulatory protein (GKRP) and of GKRP variants, to the molecular biology of certain GKRP variants, to processes for the crystallization of GKRP and GKRP variants, to such crystals and corresponding structural information obtained by X-ray crystallography. Such crystals and crystallographic data can be used for the identification of compounds that bind to GKRP, especially of compounds that inhibit GKRP or interfere with the interaction of GKRP with its natural interacting partner Glucokinase (GK).Type: ApplicationFiled: December 17, 2012Publication date: November 7, 2013Applicant: Boehringer Ingelheim International GmbHInventors: Gisela SCHNAPP, Adina Berg, Stefan Kauschke, Martin Lenter, Alexander Pautsch, Wolfgang Rist
-
Patent number: 8420630Abstract: The present invention relates to trisubstituted pyrimidines of formula (I) wherein 0Ra to Re are defined as in claim 1, which are suitable for the treatment of illnesses characterized by excessive or abnormal cell proliferation, the use thereof for preparing a pharmaceutical composition with the abovementioned properties, and processes for the preparation thereof.Type: GrantFiled: February 24, 2010Date of Patent: April 16, 2013Assignees: Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals, Inc.Inventors: Georg Dahmann, Frank Himmelsbach, Bernd Krist, Martin Lenter, Alexander Pautsch, Gisela Schnapp, Martin Steegmaier, Helmut Wittneben, Anthony S. Prokopowicz, Walter Spevak, Andreas Schoop, Steffen Steurer
-
Publication number: 20130017209Abstract: The invention relates to biparatopic A-beta binding polypeptides and, more specifically, to biparatopic A-beta binding polypeptides comprising at least two immunoglobulin single variable domains binding to different epitopes of A-beta. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as Alzheimer's Disease.Type: ApplicationFiled: September 14, 2012Publication date: January 17, 2013Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: John E. PARK, Cornelia DORNER-CIOSSEK, Stefan HOERER, Lothar KUSSMAUL, Martin LENTER, Katharina ZIMMERMANN, Gerald BESTE, Toon LAEREMANS, Pascal MERCHIERS, Jo VERCAMMEN
-
Patent number: 8337845Abstract: The invention relates to biparatopic A-beta binding polypeptides and, more specifically, to biparatopic A-beta binding polypeptides comprising at least two immunoglobulin single variable domains binding to different epitopes of A-beta. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as Alzheimer's Disease.Type: GrantFiled: March 2, 2011Date of Patent: December 25, 2012Assignee: Boehringer Ingelheim International GmbHInventors: John E. Park, Cornelia Dorner-Ciossek, Stefan Hoerer, Lothar Kussmaul, Martin Lenter, Katharina Zimmermann, Gerald Beste, Toon Laeremans, Pascal Merchiers, Jo Vercammen
-
Publication number: 20120058118Abstract: The invention relates to biparatopic A-beta binding polypeptides and, more specifically, to biparatopic A-beta binding polypeptides comprising at least two immunoglobulin single variable domains binding to different epitopes of A-beta. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as Alzheimer's Disease.Type: ApplicationFiled: March 2, 2011Publication date: March 8, 2012Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: John E. PARK, Cornelia DORNER-CIOSSEK, Stefan HOERER, Lothar KUSSMAUL, Martin LENTER, Katharina ZIMMERMANN, Gerald BESTE, Toon LAEREMANS, Pascal MERCHIERS, Jo VERCAMMEN
-
Publication number: 20100152167Abstract: The present invention relates to trisubstituted pyrimidines of formula (I) wherein 0Ra to Re are defined as in claim 1, which are suitable for the treatment of illnesses characterised by excessive or abnormal cell proliferation, the use thereof for preparing a pharmaceutical composition with the abovementioned properties, and processes for the preparation thereof.Type: ApplicationFiled: February 24, 2010Publication date: June 17, 2010Applicants: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG, BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.Inventors: Georg DAHMANN, Frank HIMMELSBACH, Bernd KRIST, Martin LENTER, Alexander PAUTSCH, Gisela SCHNAPP, Martin STEEGMAIER, Helmut WITTNEBEN, Anthony S. PROKOPOWICZ, Walter SPEVAK, Andreas SCHOOP, Steffen STEURER
-
Patent number: 7709480Abstract: The present invention relates to trisubstituted pyrimidines of formula (I) wherein 0Ra to Re are defined as in claim 1, which are suitable for the treatment of illnesses characterized by excessive or abnormal cell proliferation, the use thereof for preparing a pharmaceutical composition with the abovementioned properties, and processes for the preparation thereof.Type: GrantFiled: December 21, 2005Date of Patent: May 4, 2010Assignees: Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals, Inc.Inventors: Georg Dahmann, Frank Himmelsbach, Bernd Krist, Martin Lenter, Alexander Pautsch, Gisela Schapp, Martin Steegmaier, Helmut Wittneben, Anthony S. Prokopowicz, Walter Spevak, Andreas Schoop, Steffen Steurer
-
Publication number: 20090069282Abstract: The present invention relates to alkyne compounds of general formula I wherein the groups and residues A, B, W, X, Y, Z, R1 and R2 have the meanings given in claim 1. The invention further relates to pharmaceutical compositions containing at least one alkyne according to the invention. In view of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.Type: ApplicationFiled: May 15, 2008Publication date: March 12, 2009Applicant: Boehringer Ingelheim Pharma GmbH & Co. KGInventors: Dirk Stenkamp, Stephan Georg Mueller, Gerald Juergen Roth, Thorsten Lehmann-Lintz, Klaus Rudolf, Philipp Lustenberger, Kirsten Arndt, Ralf R. H. Lotz, Martin Lenter
-
Patent number: 7452911Abstract: The present invention relates to alkyne compounds of general formula I wherein the groups and residues A, B, W, X, Y, Z, R1 and R2 have the meanings given in claim 1. The invention further relates to pharmaceutical compositions containing at least one alkyne according to the invention. In view of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.Type: GrantFiled: October 30, 2003Date of Patent: November 18, 2008Assignee: Boehringer Ingelheim Pharma GmbH & Co. KGInventors: Dirk Stenkamp, Stephan Georg Mueller, Gerald Juergen Roth, Thorsten Lehmann-Lintz, Klaus Rudolf, Philip Lustenberger, Kirsten Arndt, Ralf R. H. Lotz, Martin Lenter
-
Patent number: 7351719Abstract: The present invention relates to amide compounds of general formula I wherein the groups and residues A, B, b, W, X, Y, Z, R1, R2 and R3 have the meanings given in claim 1. Moreover the invention relates to pharmaceutical compositions containing at least one amide according to the invention. In view of the MCH receptor-antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.Type: GrantFiled: October 31, 2003Date of Patent: April 1, 2008Assignee: Boehringer Ingelheim Pharma GmbH & Co. KGInventors: Dirk Stenkamp, Stephan Georg Mueller, Gerald Juergen Roth, Philipp Lustenberger, Klaus Rudolf, Thorsten Lehmann-Lintz, Kirsten Arndt, Ralf Lotz, Martin Lenter, Heike-Andrea Wieland
-
Patent number: 7173028Abstract: The present invention relates to trisubstituted pyrimidines of formula (I) wherein 0Ra to Re are defined as in claim 1, which are suitable for the treatment of illnesses characterised by excessive or abnormal cell proliferation, the use thereof for preparing a pharmaceutical composition with the abovementioned properties, and processes for the preparation thereof.Type: GrantFiled: October 16, 2002Date of Patent: February 6, 2007Assignees: Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals, Inc.Inventors: Georg Dahmann, Frank Himmelsbach, Bernd Krist, Martin Lenter, Alexander Pautsch, Gisela Schnapp, Martin Steegmaier, Helmut Wittneben, Anthony S. Prokopowicz, Walter Spevak, Andreas Schoop, Steffen Steurer
-
Patent number: 7166615Abstract: Indolinones of general formula I which are inhibitors of cell proliferation, particularly of tumor cells, and inhibitors of protein kinases.Type: GrantFiled: August 22, 2003Date of Patent: January 23, 2007Assignee: Boehringer Ingelheim Pharma GmbH & Co. KGInventors: Rainer Walter, Armin Heckel, Gerald Roth, Joerg Kley, Gisela Schnapp, Martin Lenter, Jacobus Van Meel, Walter Spevak, Ulrike Weyer-Czernilofsky
-
Patent number: 7160901Abstract: Indolinones of general formula I which are inhibitors of cell proliferation, particularly of tumor cells, and inhibitors of protein kinases.Type: GrantFiled: August 22, 2003Date of Patent: January 9, 2007Assignee: Boehringer Ingelheim Pharma GmbH & Co. KGInventors: Rainer Walter, Armin Heckel, Gerald Roth, Joerg Kley, Gisela Schnapp, Martin Lenter, Jacobus Van Meel, Walter Spevak, Ulrike Weyer-Czernilofsky
-
Publication number: 20060100211Abstract: The present invention relates to trisubstituted pyrimidines of formula (I) wherein 0Ra to Re are defined as in claim 1, which are suitable for the treatment of illnesses characterised by excessive or abnormal cell proliferation, the use thereof for preparing a pharmaceutical composition with the abovementioned properties, and processes for the preparation thereof.Type: ApplicationFiled: December 21, 2005Publication date: May 11, 2006Applicant: Boehringer Ingelheim Pharma GmbH & Co. KGInventors: Georg Dahmann, Frank Himmelsbach, Bernd Krist, Martin Lenter, Alexander Pautsch, Gisela Schnapp, Martin Steegmaier, Helmut Wittneben, Anthony Prokopowicz, Walter Spevak, Andreas Schoop, Steffen Steurer
-
Publication number: 20050148507Abstract: The invention relates to a process for preparing pyroGlu-MCP-1 from recombinantly produced Gln-MCP-1, wherein Gln-MCP-1 is incubated at a temperature in the range from 30° C. and 80° C. in a buffer solution with a salt concentration in the range from 10 mM to 160 mM and a pH in the range from 2 to 7.5, until at least 90% of the MCP-1 is present in the form of the pyroGlu-MCP-1.Type: ApplicationFiled: April 28, 2004Publication date: July 7, 2005Applicant: Boehringer Ingelheim International GmbHInventors: Robert Wandl, Roman Necina, Henri Doods, Martin Lenter, Randolph Seidler
-
Publication number: 20040242572Abstract: The present invention relates to carboxamide compounds of general formula I 1Type: ApplicationFiled: August 22, 2003Publication date: December 2, 2004Applicant: Boehringer Ingelheim International GmbHInventors: Dirk Stenkamp, Martin Lenter, Heike-Andrea Wieland, Klaus Rudolf, Stephan George Mueller, Ralf R.H. Lotz, Kirsten Arndt, Philipp Lustenberger, Thorsten Lehmann-Lintz